A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

ClinicalTrials.gov ID: NCT03119649

Public ClinicalTrials.gov record NCT03119649. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 19, 2026, 3:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Multiple Doses of GLPG2222 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate 4 different doses of GLPG2222 administered for 4 weeks to adult subjects with a confirmed diagnosis of CF and homozygous for the F508del Cystic Fibrosis Transmembrane conductance Regulator (CFTR) mutation.

Study identification

NCT ID: NCT03119649
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Enrollment: 59 participants

Conditions and interventions

Conditions

Cystic Fibrosis

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 17, 2017
Primary completion: Oct 18, 2017
Completion: Oct 18, 2017
Last update posted: Nov 15, 2018

2017

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
Child Health Research Unit at UAB	Chatom	Alabama	35233	—
University of Arkansas for medical Sciences	Little Rock	Arkansas	72205	—
Central Florida Pulmonary Group	Orlando	Florida	32803	—
Cystic Fibrosis Center of Chicago	Glenview	Illinois	60026	—
Maine Medical Center	Portland	Maine	04102	—
John Hopkins University School of Medicine	Baltimore	Maryland	21205	—
Medical University of South Carolina	Charleston	South Carolina	29425	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03119649, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 15, 2018 · Synced Sep 19, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03119649 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →